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Superoxide dismutase 1 (SOD1) has been implicated with familial amyotrophic lateral
sclerosis (fALS) through accumulation of protein amyloid aggregates in motor neurons
of patients. Amyloid aggregates and protein inclusions are a common pathological
feature of many neurological disorders in which protein aggregation seems to be directly
related to neurotoxicity. Although, extensive studies performed on the aggregation
process of several amyloidogenic proteins in vitro allowed the identification of many
physiological factors involved, the molecular mechanisms underlying the formation of
amyloid aggregates in vivo and in pathological conditions are still poorly understood.
Post-translational modifications are known to affect protein structure and function and,
recently, much attention has been devoted to the role played by non-enzymatic glycation
in stimulating amyloid aggregation and cellular toxicity. In particular, glycation seems to
have a determining role both in sporadic and familial forms of ALS and SOD1 has been
shown to be glycated in vivo The aim of this study was to investigate the role of glycation
on the amyloid aggregation process of both wild-type SOD1 and its ALS-related mutant
G93A. To this aim, the glycation kinetics of both native and demetalated SOD have
been followed using two different glycating agents, i.e., D-ribose and methylglyoxal. The
effect of glycation on the structure and the amyloid aggregation propensity of native and
ApoSOD has been also investigated using a combination of biophysical and biochemical
techniques. In addition, the effect of SOD glycated species on cellular toxicity and
reactive oxygen species (ROS) production has been evaluated in different cellular models.
The results provided by this study contribute to clarify the role of glycation in amyloid
aggregation and suggest a direct implication of glycation in the pathology of fALS.
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INTRODUCTION
Amyotrophic Lateral Sclerosis (ALS) is a neurological disease causing the death of motor neurons
and muscular paralysis. Although, it is predominantly a sporadic disease, 10% of ALS cases are
described as familial. Over 100 mutations, spread throughout the superoxide dismutase gene, are
associated with familial ALS (fALS) (Rosen et al., 1993; Valentine et al., 2005; Andersen, 2006;
Boillée et al., 2006; Chattopadhyay and Valentine, 2009). The presence of proteinaceous aggregates
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containing superoxide dismutase in motor neurons of patients
and transgenic model mice suggests that the aggregation of
this protein is directly related to the pathology of fALS.
Eukaryotic copper, zinc superoxide dismutase SOD1 is a 32-kDa
homodimeric metalloenzyme in which each of the two subunits
forms an eight-stranded Greek key β-barrel and contains an
active site that binds a catalytic copper ion and a structural zinc
ion. In vitro studies have shown that wild type human SOD1,
when lacking both its metal ions (ApoSOD), forms amyloid-like
oligomers under physiological conditions of pH and temperature
(Banci et al., 2007, 2008; Karch and Borchelt, 2008). Moreover, it
has been reported that also some SOD1 mutants, many of them
related to fALS (i.e., G93A) form soluble oligomeric species and
that demetallation is the key factor for aggregation (Shaw and
Valentine, 2007; Banci et al., 2008, 2009).
Amyloid aggregates and protein inclusions are a common
pathological feature of many neurological disorders such
as Huntington’s, Alzheimer’s and Parkinson’s diseases. In
these neurodegenerative diseases, misfolding, aggregation, and
precipitation of proteins seem to be directly related to
neurotoxicity. Amyloid fibrils share common structural features
despite the considerable diversity in the primary sequence
of the component proteins. In particular, they are typically
composed of unbranched fibrils (about 10 nm in diameter) rich
in β-sheet structures in which the ordered regions adopt a cross-β
structure (Serpell, 2000; Fitzpatrick et al., 2013). Although,
extensive studies performed on the aggregation process of several
amyloidogenic proteins in vitro allowed the identification of
many physiological factors involved, the molecular mechanisms
underlying the formation of amyloid aggregates in vivo and
in pathological conditions are still poorly understood. Post-
translational modifications are known to affect protein structure
and function; indeed some of them are known to affect
proteins in detrimental ways and lead to their misfolding and
accumulation. Reducing sugars play a key role in modifying
proteins, forming advanced glycation end-products (AGEs) in
a non-enzymatic process named glycation (Singh et al., 2001;
Ulrich and Cerami, 2001). Protein glycation is an irreversible,
non-enzymatic modification resulting from a chemical reaction
between reducing sugars and primary amino groups in proteins
(N-terminal, and arginine and lysine side chains). Glycation
reaction produces very reactive intermediates that can promote
the formation of intramolecular and intermolecular cross-links
within AGE-modified protein monomers. All reducing sugars
can promote glycation reactions and, between them, D-ribose
is known to be the most active and its intracellular level can
be quite high. D-glucose is the less reactive and its intracellular
concentration is negligible, while dicarbonyl compounds, such
as methylglyoxal and glyoxal, are far more reactive. Proteins in
amyloid deposits are often found glycated suggesting a direct
correlation between protein glycation and amyloidosis (Vitek
et al., 1994; Münch et al., 1997; Kikuchi et al., 2000; Shults, 2006).
In particular, glycation seems to have a determining role both in
sporadic and familial forms of ALS; in fact spinal cord and brain
samples were found to be glycated in patients (Chou et al., 1998,
1999). Moreover, SOD1 has been shown to be glycated in vivo
and glycation sites have been identified (Arai et al., 1987). Further
studies revealed that AGEs levels were high in patients carrying
SOD1 mutations and in mutant SOD1 transgenic mice, while
control cases did not display AGEs immunoreactivity (Kato et al.,
2001; Takamiya et al., 2003).
Recently, much attention has been devoted to the role played
by glycation in stimulating amyloid aggregation and cellular
toxicity. Results obtained for different protein models indicate
that, depending on the protein, glycation can both promote
amyloid aggregation or induce formation of oligomeric species,
stabilized by covalent cross-links AGE-derived, that do not
evolve into amyloid aggregates (Bouma et al., 2003; Lee et al.,
2009; Rondeau et al., 2010; Oliveira et al., 2011; Iannuzzi
et al., 2013a, 2014, 2015; Adrover et al., 2014). Also, glycation
can affect structural and physicochemical features of amyloid
oligomers as well as their interaction to the cell membrane
and subsequently modulate and/or induce the cell toxicity.
However, AGEs modified proteins are always able to affect cell
viability irrespective of amyloid properties. Indeed, the AGE-
modified proteins are tightly involved in physiopathological
cellular mechanisms through the interaction with specific cellular
receptors (RAGE) that lead to the activation of signaling
pathways involving inflammatory and apoptotic processes (Lue
et al., 2005; Vicente Miranda and Outeiro, 2010).
The aim of this study was to investigate the role of glycation
on the amyloid aggregation process of both wild-type SOD and
its fALS-related mutant G93A. To this aim, we have followed the
glycation kinetics of both native and demetalated SOD (for wild-
type and G93A mutant) using two different glycating agents, i.e.,
D-ribose andmethylglyoxal. Then, we have investigated the effect
of glycation on the structure and the aggregation propensity
of native and ApoSOD using a combination of biophysical
and biochemical techniques. In addition, we have evaluated the
effect of SOD glycated species on reactive oxygen species (ROS)
production and cellular toxicity in different cellular models. The
results provided by this study contribute to clarify the role of
glycation in amyloid aggregation and suggest a direct implication
of glycation in the pathology of fALS.
MATERIALS AND METHODS
Materials
Thioflavin T (ThT), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT), D-ribose, 2′,7′-dichlorofluorescin
diacetate, methylglyoxal, (Sigma-Aldrich Co., St. Louis, MO).
All other chemicals were of analytical grade. Methylglyoxal
was further purified by distillation under low pressure and
its concentration was determined spectrophotometrically using
ε284 = 12.3 M
−1cm−1 (Oya et al., 1999).
Cloning
cDNA encoding the human intracellular CuZnSOD was
purchased by OriGene (USA) and inserted in the pETDuet-1
vector (Novagen) by PCR using oligonucleotides that introduce
BamHI site at the initiation codon and NotI site downstream of
the stop codon. The gene encoding the yeast copper chaperone,
yCCS, was isolated from Pichia pastoris GS115 genome and
inserted in pETDuet-1 vector by PCR using oligonucleotides
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that introduce NdeI site at the initiation codon and XhoI site
downstream of the stop codon. To enable coexpression of SOD
gene and mutant variants with the yCCS in the same vector, the
chaperone gene was inserted into the respective SOD plasmids.
The SOD_G93A mutant was constructed using a
QuickChange mutagenesis kit (Stratagene). The identity of
the mutation was confirmed by DNA sequencing and mass
spectrometry of the purified proteins.
Human SOD Expression and Purification
Recombinant human SOD (WT and G93A mutant) were
co-expressed with yCCS in E. coli Rosetta-DE3 (Novagen).
Cultures grown overnight on agar-plates containing 100µg/ml
ampicillin were used to inoculate liquid cultures of 2L LB-
medium supplemented with 100µg/ml ampicillin. The cultures
were incubated at 37◦C with shaking until OD600 reached
0.5. Expression of the proteins was induced by adding 1
mM isopropyl-β-D-thiogalactoside, CuSO4 (3mM) and ZnSO4
(30µM) were also added at the time of induction. The cultures
were incubated at 20◦C overnight and the cells were harvested
by centrifugation (5000 g, 20min). The resulting pellets were
resuspended in 40ml extraction buffer (50mM phosphate,
pH 8; 300mM NaCl; 20mM imidazole; 0.001mg/ml DNase;
0.01mg/ml RNase; 0.3mM PMSF; half cocktail inhibitor tablet
Complete (Roche) and lysed by ultrasonication. The lysates were
cleared by centrifugation (15,000 g, 30min).
SOD proteins were produced with a N-ter His-tag and
purified by affinity chromatography using Ni-NTA agarose
gel (Qiagen). The collected fractions were further purified
by size exclusion chromatography on a Superdex 75 26/60
column (GE Healthcare) in 50mM phosphate, pH 8, 150mM
NaCl (Figure S1). The metal content of the purified proteins
was assessed by inductively coupled plasma atomic emission
spectroscopy (ICP-AES) and measurements of enzymatic activity
by the pyrogallol autoxidationmethod (Marklund andMarklund,
1974).
ApoSOD Preparation
Demetalated superoxide dismutase (ApoSOD) was obtained by
treating the purified metalated SOD (Holo-SOD) with 50mM
EDTA at pH 3.0. After 10min incubation at RT, the protein
was loaded on a Superdex 75 26/60 column (GE Healthcare) in
50mM phosphate, pH 8, 150mM NaCl. This procedure allows
fast refolding of the protein and getting rid of possible Holo-SOD
still present. All buffers used for Apo-proteins were treated with
Chelex 100 resin (Biorad) to remove tracemetals. The apo state of
the protein was verified by ICP-MS (Agilent Technologies, USA),
and determined to contain a molar fraction of 0.03 Zn.
Protein Glycation and Aggregation
Protein concentration was determined by absorbance
(ε280 = 5500M
−1cm−1). Glycated SOD and ApoSOD were
prepared mixing protein at a final concentration of 100µM with
0.5M D-ribose or 5mM methylglyoxal in 50mM NaH2PO4
buffer, 150mM NaCl, pH 7.4, passed through a 0.22µm filter
and incubated at 37◦C in sterile conditions. Protein in buffer
without glycating agent was used as control. Also, a control
sample having the same amount of glycating agent but without
protein was incubated under identical conditions.
For aggregation studies, protein samples were incubated at
37◦C under vigorous stirring with teflon balls, 1/8′′ diameter
(Polysciences, Inc.). Aliquots were collected in sterile conditions
before analysis.
Fluorescence Measurements
Fluorescence measurements were performed on a Perkin
Elmer Life Sciences LS 55 spectrofluorimeter. To assess the
intrinsic fluorescence of AGEs (λex 320 nm/λem 410 nm),
glycated proteins at a final concentration of 8µM were
monitored at different incubation times with the glycating
agents. The fluorescence intensity was corrected by subtracting
the emission intensity of D-ribose/methylglyoxal solutions at
different incubation times. ThT fluorescence (λex 450/λem
482 nm) was monitored at different time intervals after addition
of ThT to protein samples. Working concentrations were 8µM
for protein samples and 25µM for ThT. As there is a partial
overlap between ThT and AGEs emission spectra, the ThT
fluorescence was corrected by subtracting the emission intensity
of glycated samples before the addition of ThT.
Circular Dichroism (CD) Measurements
CD spectra were recorded at 25◦C on a JascoJ-715
spectropolarimeter using thermostated quartz cells of 0.1
cm. Spectral acquisition was taken at 0.2 nm intervals with a 4 s
integration time and a bandwidth of 1.0 nm. An average of three
scans was obtained for all spectra. Photomultiplier absorbance
did not exceed 600 V in the spectral region analyzed. All
measurements were performed under nitrogen flow and spectra
were recorded after diluting six times the stock solution (final
protein concentration 20µM). Data were corrected for buffer
contributions using the software provided by the manufacturer
(System Software version 1.00) and transformed in mean residue
ellipticity before analysis. Protein secondary structure estimation
was performed using CDPro software, which contains three
software packages, i.e., CDSSTR, CONTIN/LL, and SELCON3
(Sreerama and Woody, 2000).
Gel Electrophoresis (SDS-PAGE)
The glycation-induced oligomerization was monitored by the
protein mobility shift on SDS-PAGE (15%) using Bio-Rad (USA)
electrophoresis equipment. Ten micrograms of protein sample
were loaded and the protein bands were stained with Coomassie
Brilliant Blue.
Transmission Electronic Microscopy (TEM)
Aliquots of protein samples (3µL) were placed on the copper grid
and allowed to dry. After 5–6 min uranyl acetate replacement
stain 1X (3µL) was loaded on the grid and air dried. Images
were acquired using a Libra 120 (Zeiss) Transmission Electron
Microscope equipped withWide-angle Dual Speed CCD-Camera
sharp:eye 2K (4Mpx.).
Cell Cultures and Treatments
CPAE endothelial cells (ATCC# CCL-209) were cultured in
Minimun Essential Medium (MEM) supplemented with 10%
Frontiers in Molecular Biosciences | www.frontiersin.org 3 September 2016 | Volume 3 | Article 55
Sirangelo et al. Glycation Prevents Amyloid Aggregation in SOD1
fetal bovine calf serum (USA Origin), 2.0 mM glutamine,
100 units/mL penicillin and 100 mg/mL streptomycin in a
5.0% CO2 humidified environment at 37
◦C. SH-SY5Y human
neuroblastoma cells (ATCC# CRL-2266) were cultured in Eagle’s
Minimum Essential Medium (EMEM) supplemented with 10%
fetal bovine serum.
For all experiments, cells in culture medium without protein
and in the presence of non-glycated protein served as control.
Before incubation with cells, protein glycated in the presence
of 0.5 M D-ribose for 8 days was subjected to dialysis in sterile
conditions to remove the free glycating agent.
Cell Viability Assay
Cell viability was assessed as the inhibition of the ability of
cells to reduce the metabolic dye 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide (MTT) to a blue formazan
product (Hansen et al., 1989; Sirangelo et al., 2009). CPAE
and SH-SY5Y cells were seeded in 12-well plates at a density
of 140,000 and 250,000 cells/well respectively. After indicated
times of incubation with protein samples, cells were rinsed
with phosphate buffer solution (PBS). A stock solution of MTT
(5mg/mL in PBS) was diluted 10 times in cell medium and
incubated with cells for 3 h at 37◦C. After removing the medium,
cells were treated with isopropylalcohol, 0.1M HCl for 20min.
Levels of reduced MTT were assayed by measuring the difference
in absorbance at 570 and 690 nm. Data are expressed, as average
percentage reduction of MTT with respect to the control ±S.D.
Data are an average from five independent experiments carried
out in triplicate.
Detection of Intracellular ROS
Intracellular ROS were detected by means of an oxidation-
sensitive fluorescent probe 2′,7′-dichlorofluorescin diacetate
(DCFH-DA). EC were grown in a six-well plates, pre-incubated
with DCFH-DA for 30min and then incubated with protein
samples for 6 h. Control experiments were performed using
untreated cells. After incubation, cells were washed twice with
PBS buffer and then lysed with Tris-HCl 0.5M, pH 7.6, 1% SDS.
The non-fluorescent DCFH-DA is converted, by oxidation, to
the fluorescent molecule 2′,7′-dichlorofluorescein (DCF). DCF
fluorescence intensity was quantified on a Perkin Elmer Life
Sciences LS 55 spectrofluorimeter using an excitation wavelength
of 488 nm and an emission wavelength of 530 nm. Data are
expressed as average ±S.D. from five independent experiments
carried out in triplicate.
Statistical Analysis
For statistical analysis, we used a two-tailed Student’s t-test with
unequal variance at a significance level of 5% unless otherwise
indicated.
RESULTS AND DISCUSSION
Glycation of Human SOD and ApoSOD
Promotes Structural Changes
To check whether native SOD and ApoSOD can be glycated
in vitro, the proteins were incubated at 37◦C in the presence
of D-ribose or methylglyoxal alternatively and samples were
analyzed at different time points (days) by fluorescence
spectroscopy. Indeed, glycation of a protein results in the
appearance of a new fluorescence derivative centered at 410 nm
(λex = 320 nm) that is widely used to monitor the AGEs
formation (Matiacevich and Buera, 2006). Figure 1 shows the
time course of the emission intensity at 410 nm for SOD (A)
and ApoSOD (B) incubated with 0.5M D-ribose and 5mM
methylglyoxal. In both proteins, the fluorescence emission
intensity increased markedly with incubation time indicating
that both native SOD and ApoSOD can be glycated in vitro
in the presence of D-ribose or methylglyoxal. In particular,
methylglyoxal wasmuchmore effective thanD-ribose in affecting
the AGEs formation. Human SOD and ApoSOD alone, used as a
negative control, showed no fluorescence at 410 nm.
The dichroic activity in the far-UV region (far-UV CD) was
monitored in human SOD and ApoSOD upon glycation in order
FIGURE 1 | Glycation kinetics of human SOD and ApoSOD. Protein
glycation monitored by fluorescence spectroscopy for human SOD (A) and
ApoSOD (B). Proteins were incubated in the absence (blue) and in the
presence of 0.5M D-ribose (green) or 5mM methylglyoxal (red) and samples
analyzed by emission fluorescence (λex 320/λem 410 nm) at different time
points. Protein concentration was 8 µM, other experimental details are
described in the Materials and Methods section.
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to detect changes in the secondary structure induced by glycation.
The proteins were incubated at 37◦C in the presence and in
the absence of 0.5M D-ribose or 5mM methylglyoxal and the
samples were analyzed by CD spectroscopy at different time
points (Figures 2, 3).
In order to follow changes in the secondary structure induced
by glycation in human SOD and ApoSOD we monitored the
dichroic activity in the far-UV region (far-UV CD) upon
glycation. After incubation of each protein at 37◦C in the
presence and in the absence of 0.5M D-ribose or 5mM
methylglyoxal, samples were analyzed by CD spectroscopy at
different time points (Figures 2, 3). As expected, no difference
in the CD activity was detected for the proteins without glycating
FIGURE 2 | Effect of glycation on the secondary structure of human
SOD and ApoSOD. Time dependence of the far-UV CD activity of the human
SOD in the presence of 0.5M D-ribose (A) or 5 mM methylglyoxal (B) at
indicated time points. In (C) are shown far-UV CD spectra recorded at 2 days
of incubation for the ApoSOD in the absence (blue) and in the presence of 0.5
M D-ribose (red) or 5mM methylglyoxal (green). Experimental details are
described in the Materials and Methods section.
agent at different incubation times (data not shown). Spectra of
human SOD recorded at different times of incubation with D-
ribose or methylglyoxal are shown in Figures 2A,B respectively.
In both cases, at the beginning of the glycation reaction, the
spectrum exhibited a strong minimum at 208 nm indicative
of a predominantly beta structure conformation. Although, CD
spectra of glycated and non-glycated SOD do not exhibit strong
shape variation compared to the non-glycated protein, possess
a very similar shape, the reduction in the dichroic activity at
208 nm observed as glycation proceeds is indicative of indicate
suggests loss of beta secondary structure upon glycation. No
further variations in the dichroic activity were observed at
longer times (monitored for 30 days) and no as well as no
light scattering effects was detected, indicative of suggesting
absence of protein aggregation. Deconvolution analysis of the
CD spectra confirmed the identified a loss of beta structure
in human SOD upon glycation and a corresponding increase
of unordered fraction (Table 1). Indeed, at the beginning of
the glycation reaction, the protein possess mostly beta (34%)
and unordered structure (41%). As the reaction proceeds, the
protein loses beta-structure (around 50% after 7 days of reaction)
and gains mostly unordered structure. The results show that
Also, there is a strong correspondence between the estimated
content of secondary structure and the AGEs formation kinetics
reported in Figure 1 clearly indicating that the reduction in the
helical content beta structure is directly related to the glycation
extent. Such structural alterations induced by glycation could be
responsible for the loss of activity recently observed for native
SOD glycated in vitro in the presence of glucose, glyoxal, and
methylglyoxal (Jabeen et al., 2007; Khan et al., 2014).
Different results were obtained for demetalated ApoSOD
(Figure 2C). As expected, this protein, compared to the native
SOD, showed a lower extent of secondary structure. Indeed,
loss of metal binding is known to induce partial unfolding of
the protein and loss of activity in human SOD (Banci et al.,
2007, 2008; Chattopadhyay and Valentine, 2009). In Figure 2C
are reported the far-UV CD spectra recorded at the beginning
of the glycation process, and after 2 days of glycation in the
presence of D-ribose or methylglyoxal. No further variations in
the dichroic activity were observed at longer times (monitored
for 30 days) and no light scattering was detected, indicative of
absence of protein aggregation. These data indicate that glycation
both with D-ribose or methylglyoxal promotes fast unfolding in
ApoSOD. Also, the loss of secondary structure is much stronger
compared to that observed in the native protein indicating that
the ApoSOD ismuchmore sensitive to glycation compared to the
native SOD. Deconvolution analysis of the CD spectra confirmed
the loss of beta structure upon glycation and a corresponding
increase of unordered fraction. In Table 2 is reported the
secondary structure content for ApoSOD at different glycation
times.
Glycation of Human SOD and ApoSOD and
Oligomerization
Glycation has been indicated as a contributory factor in the
formation of high molecular weight protein species which
Frontiers in Molecular Biosciences | www.frontiersin.org 5 September 2016 | Volume 3 | Article 55
Sirangelo et al. Glycation Prevents Amyloid Aggregation in SOD1
FIGURE 3 | Effect of glycation on the oligomerization of human SOD and ApoSOD. SDS-PAGE analysis of human SOD (A) and ApoSOD (B) incubated in the
absence and in the presence of 0.5M D-ribose or 5mM methylglyoxal. Aliquots were taken at 1, 2, and 5 days of incubation at 37◦C. At each time point two different
protein concentration were analyzed: 100µM (left lane) and 200µM (right lane). Ten micrograms of protein sample were loaded for each lane. Other experimental
details are described in the Materials and Methods section.
originate from inter molecular cross-links among AGEs adducts
(Lee et al., 2009; Oliveira et al., 2011; Iannuzzi et al., 2014).
In order to monitor the increase in the apparent molecular
weight of glycated adducts, glycated species of human SOD and
ApoSOD were analyzed by SDS-PAGE in reducing conditions
(Figure 3). Samples of SOD (A) and ApoSOD (B) were analyzed
at different incubation times (1, 2, and 5 days) in the absence and
in the presence of 0.5M D-ribose or 5mM methylglyoxal at two
different molar ratio. Results shown in Figure 3A indicate that
glycation in native SOD results in an increase in the molecular
weight already at 1 day of incubation with both glycating agents.
Such increase can be ascribed to the addition of sugar molecules
to the protein. Increase of glycation extent and stabilization of
SOD dimers were observed at longer incubation times . No
higher order oligomers were observed at any time both with
D-ribose or methylglyoxal. These data indicate that glycation in
native SOD does not promote oligomerization but only covalent
dimer stabilization.
Differently, ApoSOD incubated with both D-ribose or
methylglyoxal clearly showed the appearance of high molecular
weight bands in time thus indicating that glycation promotes
the formation of covalent crosslinked oligomeric species
(Figure 3B). The process seems to be much faster in the
presence of methylglyoxal compared to D-ribose. Taken together,
these results suggest that the glycation reaction promotes
oligomerization only in ApoSOD suggesting that protein
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TABLE 1 | Secondary structure content of human SOD in the absence and
in the presence of D-ribose or methylglyoxal at different incubation times.
SOD SOD/MG SOD/Rib
Day0 Day2 Day7 Day0 Day2 Day7
α-helix 0.05 0.05 0.04 0.04 0.05 0.04 0.03
β-strand 0.34 0.34 0.20 0.18 0.34 0.27 0.19
turn 0.20 0.20 0.15 0.15 0.20 0.18 0.15
unordered 0.41 0.41 0.61 0.63 0.41 0.51 0.63
Analysis was performed as described in the Materials and Methods section and results
are expressed as percentage.
TABLE 2 | Secondary structure content of human ApoSOD in the absence
and in the presence of D-ribose or methylglyoxal at different incubation
times.
ApoSOD ApoSOD/MG ApoSOD/Rib
Day0 Day2 Day0 Day2
α-helix 0.02 0.02 0.01 0.02 0.01
β-strand 0.28 0.28 0.08 0.28 0.08
turn 0.15 0.15 0.10 0.15 0.10
unordered 0.55 0.55 0.81 0.55 0.81
Analysis was performed as described in the Materials and Methods section and results
are expressed as percentage.
glycation could be a triggering factor in the aggregation of
ApoSOD associated to fALS.
Glycation Inhibits Amyloid Fibrils
Formation in ApoSOD
Amyloid fibrils formation generally involves a series of stages
including aggregation of soluble oligomers through unspecific
interactions, formation of protofibrillar structures and eventually
their assembly into mature fibrils through a nucleation and
elongation process (Lee et al., 2007; Fitzpatrick et al., 2013;
Iannuzzi et al., 2013b; Knowles et al., 2014). Generally, oligomeric
intermediates are the most toxic species compared to the mature
fibrils (Malmo et al., 2006; Iannuzzi et al., 2007; Vilasi et al.,
2008; Stefani, 2012; Sirangelo et al., 2014). ApoSOD is known
to form amyloid aggregates in native conditions at 37◦C upon
perturbation (stirring) (Banci et al., 2007, 2008). In order to
study the effect of glycation on the aggregation process of the
human SOD, we tested the ability of glycated SOD and ApoSOD
to form amyloid aggregates in native conditions upon stirring.
To this aim, human SOD and ApoSOD glycated by D-ribose or
methylglyoxal for 8 days were incubated at 37◦C upon stirring
and samples were analyzed at different times of incubation
(up to 60 days) by ThT fluorescence assay. ThT fluorescence
is a widely used method for detecting amyloid formation as
ThT specifically binds amyloid structures exhibiting a strong
fluorescence increase (LeVine, 1993). In Figure 4 is reported the
ThT fluorescence intensity at 10 days of incubation in aggregation
conditions. As expected, the non-glycated ApoSOD is able to
bind ThT thus indicating the formation of amyloid species upon
FIGURE 4 | Effect of glycation on the amyloid aggregation of human
SOD and ApoSOD. Human SOD and ApoSOD glycated in the presence of
0.5M D-ribose or 5mM methylglyoxal for 8 days were incubated under stirring
at 37◦C and analyzed at 10 days of incubation by ThT fluorescence assay.
Similarly, samples incubated in the absence of glycating agent were also
tested. ThT fluorescence emission was recorded at 482 nm upon excitation at
450 nm. Other experimental conditions are described in the Materials and
Methods section.
stirring. Interestingly, no ThT fluorescence increase was detected
for the glycated sample clearly indicating that glycation inhibits
amyloid formation in ApoSOD. Similar results were obtained
for glycated samples at longer incubation time (up to 60 days).
Differently to apoSOD, the native SOD is unable to form amyloid
aggregates upon stirring at 37◦C (Banci et al., 2007, 2008). As
expected, no ThT fluorescence increase was observed for native
SOD in aggregating conditions. Interestingly, also the glycated
samples did not show ThT fluorescence thus indicating that
glycation does not promote amyloid formation in native SOD.
Taken together, these results strongly suggest that glycation
with both D-ribose or methylglyoxal strongly inhibits amyloid
fibrils formation in ApoSOD and does not promote amyloid
aggregation in native SOD. Transmission electron microscopy
(TEM) measurements further confirmed these data (Figure 5).
Indeed, consistent with the ThT staining, the TEM images
recorded for ApoSOD at 10 days of incubation in aggregation
conditions revealed the presence of mature fibrils only in the
absence of glycating agent. No prefibrillar aggregates and/or
mature fibrils were detected in the sample glycated with D-ribose.
Similar results were obtained in the presence of methylglyoxal.
Cytotoxicity of Glycated SOD and ApoSOD
As oligomeric intermediates are the most toxic species respect to
mature fibrils, to better clarify the role of glycation in amyloid
aggregation, viability of cells exposed to ribose-glycated SOD
and ApoSOD before and after 10 days of aggregating conditions
(stirring at 37◦C) was also evaluated (Figure 6). The cytotoxicity
of such glycated protein was studied in both endothelial (CPAE)
and neurotypical (SHSY5Y) cell lines and very similar results
were obtained for both cellular models.
As expected, no toxicity was detected for the native SOD both
before and after aggregating conditions. Interestingly, a weak
toxicity was shown for glycated forms. In particular, the same
extent of toxicity was observed for glycated SOD both before and
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after stirring thus indicating that toxicity is not related to the
formation of cytotoxic oligomers but only to glycated products
(Figure 6A).
FIGURE 5 | Transmission electron microscopy. ApoSOD glycated in the
absence (A) and in the presence (B) of 0.5 M D-ribose for 8 days was
incubated under stirring at 37◦C and analyzed at 10 days of incubation by
TEM microscopy. Experimental details are described in the Materials and
Methods section.
FIGURE 6 | Effect of glycated SOD and ApoSOD on cell viability.
SH-SY5Y cells were exposed for 24 h to different SOD (A) and ApoSOD
samples (B) and cell viability was evaluated by MTT assay. Protein incubated
in the absence (SOD/ApoSOD) and in the presence (SOD_Rib/ApoSOD_Rib)
of D-ribose for 8 days. These samples were also tested after 10 days in
aggregation conditions (_stirring). CTR represents untreated cells. Data are
expressed as average percentage of MTT reduction ±SD relative to control
cells from triplicate wells from 5 separate experiments (p < 0.01). Protein
concentration was 20µM, other experimental conditions are described in the
Materials and Methods section.
When the cells were incubated with ApoSOD no cytotoxicity
was shown as expected. Similarly, the ApoSOD incubated for
10 days upon stirring did not alter cell viability indicating
that amyloid fibrils formed upon stirring are harmless. On
the contrary, the cell viability decreased significantly when
cells were exposed to the glycated ApoSOD (Figure 6B).
In particular, glycated ApoSOD was able to induce strong
cytotoxicity both before and after stirring. The strong MTT
reduction (around 40%) observed in cells exposed to the glycated
proteins suggests that glycation promotes the formation of
highly cytotoxic species AGEs-associated, although inhibiting
amyloid aggregation in ApoSOD. These results suggest that the
non-amyloidogenic oligomers are the species responsible for
cytotoxicity.
Indeed, AGEs modified proteins are known to affect
cell viability through the interaction with specific cellular
receptors (RAGE) that lead to the activation of signaling
pathways involving inflammatory and apoptotic processes
and irrespectively of their amyloid properties. (Lue et al.,
2005; Vicente Miranda and Outeiro, 2010). Also, the higher
toxicity observed for the glycated ApoSOD compared to
the native SOD could be associated to its higher degree of
glycation.
Moreover, to test whether oxidative stress plays an important
role in the cell death associated to glycated SOD and ApoSOD, we
measured the intracellular ROS levels using the redox-sensitive
fluorescent dye DCFH-DA (Figure 7). Cell exposed to the native
SOD showed reduced production of intracellular ROS compared
to control cells, probably due to the intrinsic antioxidant
activity of the protein, while cell exposed to ApoSOD were not.
This might be due to the loss of activity in the demetalated
protein. Interestingly, both glycated SOD and ApoSOD were
able to trigger intracellular ROS production. This effect might
be associated to the loss of activity in the native SOD upon
glycation and to the ability of AGEs products to induce oxidative
stress (Jabeen et al., 2007; Wei et al., 2009; Kong et al., 2011;
Khan et al., 2014). This observation is in line with previous
FIGURE 7 | Effect of glycated SOD and ApoSOD on ROS production.
ROS levels measured by the DCFH-DA fluorescence assay as described in
Material and Methods section. SH-SY5Y cells were exposed for 6 h to SOD
and ApoSOD previously incubated in the presence and in the absence of
D-ribose for 8 days. CTR represents untreated cells. Protein concentration
was 20µM, other experimental conditions are described in the Materials and
Methods section.
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reports showing that ROS production increases in AGEs-induced
toxicity for several cell lines (Yamagishi and Takeuchi, 2004; Khan
et al., 2013; Iannuzzi et al., 2016). An important issue dealing with
the signaling cascade evoked by AGE treatment is themechanism
by which it causes oxidative stress. Previous studies indicate that
AGE proteins prepared in vitro possess similar cross-reactive
AGE epitopes that are common to proteins modified by AGEs
in vivo and that interaction of these molecules with RAGE
is associated with ROS generation (Kislinger et al., 1999; Han
et al., 2011, 2014). Thus, the ROS production observed in cells
exposed to glycated SOD and ApoSOD could be associated
to signaling pathways activated by the RAGE-AGE interaction.
Further studies will be needed to better clarify the molecular
mechanisms underlying the cytotoxicity induced by glycated
SOD and ApoSOD.
Human G39A_SOD Glycation and
Oligomerization
The effect of glycation was also monitored for the fALS-
related mutant SOD_G93A. The G93A is one of the most
severe mutation associated to fALS and it has been reported
to strongly destabilize the apo-state of the protein leading to
fast formation of amyloid fibrils in physiological conditions
(Shaw and Valentine, 2007; Banci et al., 2008, 2009; Karch
FIGURE 8 | Glycation kinetics and oligomerization of G93A_SOD and G93A_ApoSOD. Glycation kinetics and oligomerization monitored by fluorescence
spectroscopy (λex 320 nm/λem 410 nm) and SDS-PAGE for G93A_SOD (A) and G93A_ApoSOD (B). Proteins were incubated in the absence (blue) and in the
presence of 0.5 M D-ribose (green) or 5 mM methylglyoxal (red) and samples were analyzed at different time points. Other experimental details are described in the
Materials and Methods section.
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et al., 2009; Luchinat et al., 2014). Figure 8 shows the glycation
kinetics recorded for the G93A_SOD (A) and ApoG93A_SOD
(B) by AGEs fluorescence and SDS-PAGE analysis. The proteins
were incubated in the presence of 0.5 M D-ribose or 5 mM
methylglyoxal and samples analyzed at different time points. As
for the wild-type protein, the glycation extent is much higher in
the Apo-G93A compared to the G93A protein thus suggesting a
higher exposure of glycation sites in the demetalated form. Also,
comparing these results with those obtained for the wild-type
protein (Figure 1), the relative AGEs fluorescence intensities are
much higher in the mutant thus suggesting that the G93A_SOD
mutant is much more susceptible to glycation respect to the wild-
type protein. These results are in perfect agreement with data
obtained in vivo by Takamiya and coworkers showing a higher
degree of glycation in the G93A_SOD mutant compared to the
wild type protein. In this paper they also suggest that the higher
susceptibility of mutated SOD to glycation in vivo is an important
factor in the pathogenesis of fALS (Takamiya et al., 2003).
Glycated samples analyzed by SDS-PAGE show that glycation
with both D-ribose or methylglyoxal promotes covalent
dimerization in the G93A_SOD and high oligomerization in
the ApoG93A_SOD. Also in this respect, the effect of glycation
on protein oligomerization of G93A_SOD is similar to that
observed for the wild-type protein.
In addition, we tested the ability of glycated G93A_SOD
and ApoG93A_SOD to form amyloid aggregates at physiological
conditions of pH and temperature under stirring. The non-
glycated proteins were used for comparison. As for the wild-type
protein, both the G93A_SOD and its glycated form were unable
to form amyloid aggregates as suggested by the absence of ThT
fluorescence (data not shown). These data indicate that, as for the
wild-type protein, glycation does not promote amyloid formation
in the G93A_SOD mutant.
Different results were obtained for the Apo G93A_SOD. As
expected, this protein has a strong propensity to form amyloid
aggregates compared to the wild-type protein, as indicated by an
early appearance of ThT fluorescence at 2 days in aggregating
condition (Figure 9A). Differently, ThT fluorescence increase
was detected for the wild type Apo protein at 8–10 days
of incubation. Such higher aggregation propensity could be
associated to a strong destabilization of the apo-structure in the
mutant, as suggested by far-UV CD spectroscopy (Figure S2).
Interestingly, as observed for the wild type ApoSOD, no ThT
fluorescence was observed for glycated ApoG93A_SOD in time,
thus indicating that glycation inhibits amyloid aggregation also
in the amyloidogenic mutant. Moreover, the same samples
analyzed for ThT fluorescence were tested for cytotoxicity by
MTT assay (Figure 9B). No toxicity was observed for the
non-glycated ApoG93A_SOD at any aggregation time being
in the harmless fibrillar state. Differently, the glycated species
altered the cell viability in a time-dependent manner related to
the AGE extent as observed for the wild-type protein. These
data suggest that glycation, even in the strongly amyloidogenic
ApoG93A_SOD mutant, is able to inhibit amyloid aggregation
also at early stage of the aggregation process . However, the
glycated species show an intrinsic toxicity related to the AGEs
formation.
FIGURE 9 | Effect of glycation on the amyloid aggregation and
cytotoxicity of G93A_ApoSOD. G93A_ApoSOD glycated in the presence
and in the absence of D-ribose for 8 days were incubated under stirring at
37◦C and analyzed at different time points (days) by ThT fluorescence assay
(A). The same samples were tested for cytotoxicity by the MTT assay (B). CTR
represents untreated cells. Data are expressed as average percentage of MTT
reduction ±SD relative to control cells from triplicate wells from 5 separate
experiments (p < 0.01). Other experimental conditions are described in the
Materials and Methods section.
CONCLUSIONS
The present study clearly shows that both native SOD and
ApoSOD can be efficiently glycated in vitro by D-ribose or
methylglyoxal and glycation seems to induce protein unfolding
and loss of secondary structure. As observed for other model
proteins, the effect of glycation on amyloid aggregation may
not be generalized as strongly depending on the protein
structure. Indeed, protein glycation, being a post-translational
modification, can differently affect the aggregation process in
promoting, accelerating and/or stabilizing on-pathway and off-
pathway species.
Results obtained on native SOD indicate that glycation does
not promote amyloid aggregation in this protein. At the same
time, glycation strongly inhibits amyloid aggregation in the
amyloidogenic Apo-state of the protein both for the wild type
and for the G93A fALS-related mutant. In addition, AGEs-
modified SOD and ApoSOD were shown to induce cell toxicity
and oxidative stress in different cellular models which may be
likely mediated by the interaction of AGE-modified proteins
with RAGE. Further studies will be needed to better clarify the
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molecular mechanisms underlying the cytotoxicity induced by
the AGE-modified SOD.
In conclusion, these data suggest that glycation is unlikely
to be a triggering factor in SOD amyloid aggregation in vivo.
However, the cytotoxicity induced by SOD glycated species
suggests that glycation could directly interfere with fALS
pathogenesis through the signaling pathways activated by the
AGEs species.
AUTHOR CONTRIBUTIONS
Conceived and designed the experiments, CI, FV, IS, GM, and
GI; Performed the experiments, FV, CI; Analyzed the data, FV,
CI, and IS; Contributed reagents/materials/analysis tools, CI, IS,
and GM; Wrote the paper, CI.
FUNDING
This work was supported by a grant from MIUR
(Finanziamento per Rientro dei Cervelli “Rita Levi Montalcini”),
and “Regione Campania (L.R. N.5- 28.03.2002)”. The
funders had no role in study design, data collection and
analysis, the decision to publish, or preparation of the
manuscript.
ACKNOWLEDGMENTS
The authors wish to thank the “Electron Microscopy” Facility of
the Department of Experimental Medicine—“Laboratorio
Grandi Attrezzature”—Second University of Naples,
and Marcella Cammarota for her skilled technical
support.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: http://journal.frontiersin.org/article/10.3389/fmolb.
2016.00055
REFERENCES
Adrover, M., Mariño, L., Sanchis, P., Pauwels, K., Kraan, Y., Lebrun, P.,
et al. (2014). Mechanistic insights in glycation-induced protein aggregation.
Biomacromolecules 15, 3449–3462. doi: 10.1021/bm501077j
Andersen, P. M. (2006). Amyotrophic lateral sclerosis associated with mutations
in the CuZn superoxide dismutase gene. Curr. Neurol. Neurosci. Rep. 6, 37–46.
doi: 10.1007/s11910-996-0008-9
Arai, K., Maguchi, S., Fujii, S., Ishibashi, H., Oikawa, K., and Taniguchi, N.
(1987). Glycation and inactivation of human Cu-Zn-superoxide dismutase.
Identification of the in vitro glycated sites. J. Biol. Chem. 262, 16969–16972.
Banci, L., Bertini, I., Boca, M., Calderone, V., Cantini, F., Girotto, S., et al.
(2009). Structural and dynamic aspects related to oligomerization of apo
SOD1 and its mutants. Proc. Natl. Acad. Sci. U.S.A. 106, 6980–6985.
doi:10.1073/pnas.0809845106
Banci, L., Bertini, I., Boca, M., Girotto, S., Martinelli, M., Valentine, J. S.,
et al. (2008). SOD1 and amyotrophic lateral sclerosis: mutations and
oligomerization. PLoS ONE 3:e1677. doi: 10.1371/journal.pone.0001677
Banci, L., Bertini, I., Durazo, A., Girotto, S., Gralla, E. B., Martinelli, M.,
et al. (2007). Metal-free superoxide dismutase forms soluble oligomers under
physiological conditions: a possible general mechanism for familial ALS. Proc.
Natl. Acad. Sci. U.S.A. 104, 11263–11267. doi: 10.1073/pnas.0704307104
Boillée, S., Vande Velde, C., and Cleveland, D. W. (2006). ALS: a disease of
motor neurons and their nonneuronal neighbors. Neuron 52, 39–59. doi:
10.1016/j.neuron.2006.09.018
Bouma, B., Kroon-Batenburg, L. M., Wu, Y. P., Brünjes, B., Posthuma, G.,
Kranenburg, O., et al. (2003). Glycation induces formation of amyloid
cross-beta structure in albumin. J. Biol. Chem. 278, 41810–41819. doi:
10.1074/jbc.M303925200
Chattopadhyay, M., and Valentine, J. S. (2009). Aggregation of copper-zinc
superoxide dismutase in familial and sporadic ALS. Antioxid. Redox Signal. 11,
1603–1614. doi: 10.1089/ARS.2009.2536
Chou, S. M., Han, C. Y., Wang, H. S., Vlassara, H., and Bucala, R. (1999).
A receptor for advanced glycosylation endproducts (AGEs) is colocalized
with neurofilament-bound AGEs and SOD1 in motoneurons of ALS:
immunohistochemical study. J. Neurol. Sci. 169, 87–92. doi: 10.1016/S0022-
510X(99)00222-1
Chou, S. M., Wang, H. S., Taniguchi, A., and Bucala, R. (1998). Advanced glycation
endproducts in neurofilament conglomeration of motoneurons in familial and
sporadic amyotrophic lateral sclerosis.Mol. Med. 4, 324–332.
Fitzpatrick, A. W., Debelouchina, G. T., Bayro, M. J., Clare, D. K., Caporini, M.
A., Bajaj, V. S., et al. (2013). Atomic structure and hierarchical assembly of
a cross-β amyloid fibril. Proc. Natl. Acad. Sci. U.S.A. 110, 5468–5473. doi:
10.1073/pnas.1219476110
Han, C., Lu, Y., Wei, Y., Liu, Y., and He, R. (2011). D-ribose induces cellular
protein glycation and impairs mouse spatial cognition. PLoS ONE 6:e24623.
doi: 10.1371/journal.pone.0024623
Han, C., Lu, Y., Wei, Y., Wu, B., Liu, Y., and He, R. (2014). D-ribosylation induces
cognitive impairment through RAGE-dependent astrocytic inflammation. Cell.
Death Dis. 5:1117. doi: 10.1038/cddis.2014.89
Hansen, M. B., Nielsen, S. E., and Berg, K. (1989). Re-examination and further
development of a precise and rapid dye method for measuring cell growth/cell
kill. J. Immunol. Methods 119, 203–210.
Iannuzzi, C., Borriello, M., Carafa, V., Altucci, L., Vitiello, M., Balestrieri, M.
L., et al. (2016). D-ribose-glycation of insulin prevents amyloid aggregation
and produces cytotoxic adducts. Biochim. Biophys. Acta 1862, 93–104. doi:
10.1016/j.bbadis.2015.10.021
Iannuzzi, C., Carafa, V., Altucci, L., Irace, G., Borriello, M., Vinciguerra, R.,
et al. (2015). Glycation of wild-type apomyoglobin induces formation of
highly cytotoxic oligomeric species. J. Cell Physiol. 230, 2807–2820. doi:
10.1002/jcp.25011
Iannuzzi, C., Irace, G., and Sirangelo, I. (2014). Differential effects of glycation
on protein aggregation and amyloid formation. Front. Mol. Biosci. 1:9. doi:
10.3389/fmolb.2014.00009
Iannuzzi, C., Maritato, R., Irace, G., and Sirangelo, I. (2013a). Glycation accelerates
fibrillization of the amyloidogenic W7FW14F apomyoglobin. PLoS ONE
8:e80768. doi: 10.1371/journal.pone.0080768
Iannuzzi, C., Maritato, R., Irace, G., and Sirangelo, I. (2013b). Misfolding and
amyloid aggregation of apomyoglobin. Int. J. Mol. Sci. 14, 14287–14300. doi:
10.3390/ijms140714287
Iannuzzi, C., Vilasi, S., Portaccio, M., Irace, G., and Sirangelo, I. (2007).
Heme binding inhibits the fibrillization of amyloidogenic apomyoglobin and
determines lack of aggregate cytotoxicity. Protein Sci. 16, 507–516. doi:
10.1110/ps.062471107
Jabeen, R., Saleemuddin, M., Petersen, J., and Mohammad, A. (2007). Inactivation
andmodification of superoxide dismutase by glyoxal: prevention by antibodies.
Biochimie 89, 311–318. doi: 10.1016/j.biochi.2006.10.015
Karch, C. M., and Borchelt, D. R. (2008). A limited role for disulfide cross-linking
in the aggregation of mutant SOD1 linked to familial amyotrophic lateral
sclerosis. J. Biol. Chem. 283, 13528–13537. doi: 10.1074/jbc.M800564200
Karch, C. M., Prudencio, M., Winkler, D. D., Hart, P. J., and Borchelt, D. R.
(2009). Role of mutant SOD1 disulfide oxidation and aggregation in the
pathogenesis of familial ALS. Proc. Natl. Acad. Sci. U.S.A. 106, 7774–7779. doi:
10.1073/pnas.0902505106
Frontiers in Molecular Biosciences | www.frontiersin.org 11 September 2016 | Volume 3 | Article 55
Sirangelo et al. Glycation Prevents Amyloid Aggregation in SOD1
Kato, S., Nakashima, K., Horiuchi, S., Nagai, R., Cleveland, D. W., Liu, J., et al.
(2001). Formation of advanced glycation end-product-modified superoxide
dismutase-1 (SOD1) is one of the mechanisms responsible for inclusions
common to familial amyotrophic lateral sclerosis patients with SOD1 gene
mutation, and transgenic mice expressing human SOD1 gene mutation.
Neuropathology 21, 67–81. doi: 10.1111/j.1440-1789.2001.00359.x
Khan, M. A., Anwar, S., Aljarbou, A. N., Al-Orainy, M., Aldebasi, Y. H., Islam, S.,
et al. (2014). Protective effect of thymoquinone on glucose or methylglyoxal-
induced glycation of superoxide dismutase. Int. J. Biol. Macromol. 65, 16–20.
doi: 10.1016/j.ijbiomac.2014.01.001
Khan, M. S., Dwivedi, S., Priyadarshini, M., Tabrez, S., Siddiqu, M. A., Jagirdar, H.,
et al. (2013). Ribosylation of bovine serum albumin induces ROS accumulation
and cell death in cancer line (MCF-7). Eur. Biophys. J. 42, 811–818. doi:
10.1007/s00249-013-0929-6
Kikuchi, S., Ogata, A., Shinpo, K., Moriwaka, F., Fujii, J., Taniguchi, N., et al.
(2000). Detection of an Amadori product, 1-hexitol-lysine, in the anterior horn
of the amyotrophic lateral sclerosis and spinobulbar muscular atrophy spinal
cord: evidence for early involvement of glycation in motoneuron diseases. Acta
Neuropathol. 99, 63–66. doi: 10.1007/PL00007407
Kislinger, T., Fu, C., Huber, B., Qu, W., Taguchi, A., Du Yan, S., et al.
(1999). N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for
receptor for advanced glycation end products that activate cell signaling
pathways and modulate gene expression. J. Biol. Chem. 274, 31740–31749. doi:
10.1074/jbc.274.44.31740
Knowles, T. P., Vendruscolo, M., and Dobson, C. M. (2014). The amyloid state
and its association with protein misfolding diseases.Nat. Rev. Mol. Cell Biol. 15,
384–396. doi: 10.1038/nrm3810
Kong, F. L., Cheng, W., Chen, J., and Liang, Y. (2011). D-Ribose glycates
β(2)-microglobulin to form aggregates with high cytotoxicity through
a ROS-mediated pathway. Chem. Biol. Interact. 194, 69–78. doi:
10.1016/j.cbi.2011.08.003
Lee, C. C., Nayak, A., Sethuraman, A., Belfort, G., and McRae, G. J. (2007). A
three-stage kinetic model of amyloid fibrillation. Biophys. J. 92, 3448–3458. doi:
10.1529/biophysj.106.098608
Lee, D., Park, C. W., Paik, S. R., and Choi, K. Y. (2009). The modification of alpha-
synuclein by dicarbonyl compounds inhibits its fibril-forming process. Biochim.
Biophys. Acta 1794, 421–430. doi: 10.1016/j.bbapap.2008.11.016
LeVine, H, IIIrd. (1993). Thioflavine T interaction with synthetic Alzheimer’s
disease beta-amyloid peptides: detection of amyloid aggregation in solution.
Protein Sci. 2, 404–410. doi: 10.1002/pro.5560020312
Luchinat, E., Barbieri, L., Rubino, J. T., Kozyreva, T., Cantini, F., and Banci, L.
(2014). In-cell NMR reveals potential precursor of toxic species from SOD1
fALS mutants. Nat. Commun. 5:5502. doi: 10.1038/ncomms6502
Lue, L. F., Yan, S. D., Stern, D. M., and Walker, D. G. (2005). Preventing activation
of receptor for advanced glycation endproducts in Alzheimer’s disease. Curr.
Drug Targets CNS Neurol. Disord. 4, 249–266. doi: 10.2174/1568007054038210
Malmo, C., Vilasi, S., Iannuzzi, C., Tacchi, S., Cametti, C., Irace, G., et al. (2006).
Tetracycline inhibits W7FW14F apomyoglobin fibril extension and keeps the
amyloid protein in a pre-fibrillar, highly cytotoxic state. FASEB J. 20, 346–347.
doi: 10.1096/fj.05-4652fje
Marklund, S., and Marklund, G. (1974). Involvement of the superoxide anion
radical in the autoxidation of pyrogallol and a convenient assay for
superoxide dismutase. Eur. J. Biochem. 47, 469–474. doi: 10.1111/j.1432-
1033.1974.tb03714.x
Matiacevich, S. B., and Buera, M. P. (2006). A critical evaluation of fluorescence
as a potential marker for the Maillard reaction. Food Chem. 95, 423–430. doi:
10.1016/j.foodchem.2005.01.027
Münch, G., Mayer, S., Michaelis, J., Hipkiss, A. R., Riederer, P., Müller, R., et al.
(1997). Influence of advanced glycation end-products and AGE-inhibitors
on nucleation-dependent polymerization of beta-amyloid peptide. Biochim.
Biophys. Acta 1360, 17–29. doi: 10.1016/S0925-4439(96)00062-2
Oliveira, L. M., Lages, A., Gomes, R. A., Neves, H., Família, C., Coelho, A. V., et al.
(2011). Insulin glycation bymethylglyoxal results in native-like aggregation and
inhibition of fibril formation. BMC Biochem. 12:41. doi: 10.1186/1471-2091-
12-41
Oya, T., Hattori, N., Mizuno, Y., Miyata, S., Maeda, S., Osawa, T., et al.
(1999). Methylglyoxal modification of protein. Chemical and immunochemical
characterization of methylglyoxal-arginine adducts. J. Biol. Chem. 274,
18492–502.
Rondeau, P., Navarra, G., Cacciabaudo, F., Leone, M., Bourdon, E., and Militello,
V. (2010). Thermal aggregation of glycated bovine serum albumin. Biochim.
Biophys. Acta 1804, 789–798. doi: 10.1016/j.bbapap.2009.12.003
Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A.,
et al. (1993). Mutations in Cu/Zn superoxide dismutasegene are associated with
familial amyotrophic lateral sclerosis. Nature 362, 59–62.
Serpell, L. C. (2000). Alzheimer’s amyloid fibrils: structure and assembly.
Biochim. Biophys. Acta 1502, 16–30. doi: 10.1016/S0925-4439(00)
00029-6
Shaw, B. F., and Valentine, J. S. (2007). How do ALS-associated mutations in
superoxide dismutase 1 promote aggregation of the protein? Trends Biochem.
Sci. 32, 78–85. doi: 10.1016/j.tibs.2006.12.005
Shults, C. W. (2006). Lewy bodies. Proc. Natl. Acad. Sci. U.S.A. 103, 1661–1668.
doi: 10.1073/pnas.0509567103
Singh, R., Barden, A., Mori, T., and Beilin, L. (2001). Advanced glycation
end-products: a review. Diabetologia 44, 129–146. doi: 10.1007/s0012500
51591
Sirangelo, I., Giovane, A., Maritato, R., D’Onofrio, N., Iannuzzi, C., Giordano,
A., et al. (2014). Platelet-activating factor mediates the cytotoxicity induced
byW7FW14F apomyoglobin amyloid aggregates in neuroblastoma cells. J. Cell
Biochem. 115, 2116–2122. doi: 10.1002/jcb.24888
Sirangelo, I., Iannuzzi, C., Vilasi, S., Irace, G., Giuberti, G., Misso, G., et al. (2009).
W7FW14F apomyoglobin amyloid aggregates-mediated apoptosis is due to
oxidative stress and AKT inactivation caused by Ras and Rac. J. Cell Physiol.
221, 412–423. doi: 10.1002/jcp.21871
Sreerama, N., and Woody, R. W. (2000). Estimation of protein secondary
structure from circular dichroism spectra: comparison of CONTIN, SELCON,
and CDSSTR methods with an expanded reference set. Anal. Biochem. 287,
252–260. doi: 10.1006/abio.2000.4880
Stefani, M. (2012). Structural features and cytotoxicity of amyloid oligomers:
implications in Alzheimer’s disease and other diseases with amyloid deposits.
Prog. Neurobiol. 99, 226–245. doi: 10.1016/j.pneurobio.2012.03.002
Takamiya, R., Takahashi, M., Myint, T., Park, Y. S., Miyazawa, N., Endo, T., et al.
(2003). Glycation proceeds faster in mutated Cu, Zn-superoxide dismutases
related to familial amyotrophic lateral sclerosis. FASEB J. 17, 938–940. doi:
10.1096/fj.02-0768fje
Ulrich, P., and Cerami, A. (2001). Protein glycation, diabetes, and aging. Recent
Prog. Horm. Res. 56, 1–21. doi: 10.1210/rp.56.1.1
Valentine, J. S., Doucette, P. A., and Zittin Potter, S. (2005). Copper-zinc
superoxide dismutase and amyotrophic lateral sclerosis. Annu. Rev. Biochem.
74, 563–593. doi: 10.1146/annurev.biochem.72.121801.161647
VicenteMiranda, H., and Outeiro, T. F. (2010). The sour side of neurodegenerative
disorders: the effects of protein glycation. J. Pathol. 221, 13–25. doi:
10.1002/path.2682
Vilasi, S., Iannuzzi, C., Portaccio, M., Irace, G., and Sirangelo, I. (2008). Effect of
trehalose on W7FW14F apomyoglobin and insulin fibrillization: new insight
into inhibition activity. Biochemistry 47, 1789–1796. doi: 10.1021/bi701530w
Vitek, M. P., Bhattacharya, K., Glendening, J. M., Stopa, E., Vlassara, H., Bucala,
R., et al. (1994). Advanced glycation end products contribute to amyloidosis
in Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 91, 4766–4770. doi:
10.1073/pnas.91.11.4766
Wei, Y., Chen, L., Chen, J., Ge, L., and He, R. Q. (2009). Rapid glycation with D-
ribose induces globular amyloid-like aggregations of BSAwith high cytotoxicity
to SH-SY5Y cells. BMC Cell Biol. 10:10. doi: 10.1186/1471-2121-10-10
Yamagishi, S., and Takeuchi, M. (2004). Nifedipine inhibits gene expression of
receptor for advanced glycation end products (RAGE) in endothelial cells
by suppressing reactive oxygen species generation. Drugs Exp. Clin. Res. 30,
169–175.
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Sirangelo, Vella, Irace,Manco and Iannuzzi. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Molecular Biosciences | www.frontiersin.org 12 September 2016 | Volume 3 | Article 55
